IDH2 Gene

• The IDH2 gene encodes isocitrate dehydrogenase 2, an enzyme vital for the Krebs cycle and NADPH production.
• Its primary function involves converting isocitrate to alpha-ketoglutarate, crucial for cellular energy and antioxidant processes.
• Mutations in the IDH2 gene can lead to a neomorphic enzyme activity, producing the oncometabolite 2-hydroxyglutarate.
• These mutations are frequently associated with various cancers, including acute myeloid leukemia and cholangiocarcinoma.
• Targeting IDH2 mutations has become a significant strategy in precision oncology.

What is the IDH2 Gene and Its Function?

The IDH2 gene, or Isocitrate Dehydrogenase 2 gene, provides instructions for making the mitochondrial enzyme isocitrate dehydrogenase 2. This enzyme is a key component of the Krebs cycle (also known as the citric acid cycle or TCA cycle), which is the central metabolic pathway for generating energy in aerobic organisms. Located in the mitochondria, IDH2 catalyzes the oxidative decarboxylation of isocitrate to alpha-ketoglutarate (α-KG).

A crucial aspect of IDH2 gene function is its role in producing NADPH (nicotinamide adenine dinucleotide phosphate). During the conversion of isocitrate to α-KG, IDH2 reduces NADP+ to NADPH. NADPH is vital for several cellular processes, including:

• Protecting cells from oxidative stress by regenerating reduced glutathione, a major antioxidant.
• Supporting anabolic pathways, such as fatty acid and cholesterol synthesis.
• Regulating epigenetic modifications through its influence on α-KG levels, which are cofactors for various dioxygenases.

This dual role in energy metabolism and antioxidant defense underscores the importance of IDH2 for overall cellular health and function.

IDH2 Gene Mutations and Associated Diseases

A IDH2 gene mutation typically involves a single amino acid change in the enzyme, most commonly at arginine 140 (R140) or arginine 172 (R172). These specific mutations do not simply inactivate the enzyme; instead, they confer a “neomorphic” activity. This means the mutated enzyme gains a new function: it catalyzes the reduction of alpha-ketoglutarate to D-2-hydroxyglutarate (2-HG), an oncometabolite. Elevated levels of 2-HG can inhibit several α-KG-dependent enzymes, including histone demethylases and TET (ten-eleven translocation) DNA demethylases. This inhibition leads to widespread epigenetic alterations, affecting gene expression and promoting oncogenesis.

The presence of these mutations is a hallmark in the diagnosis and treatment of several IDH2 gene related diseases, primarily various forms of cancer. For instance, IDH2 mutations are found in approximately 10-15% of patients with acute myeloid leukemia (AML), a rapidly progressing cancer of the blood and bone marrow. (Source: American Cancer Society). They are also observed in other malignancies, including:

• Cholangiocarcinoma (bile duct cancer)
• Gliomas (brain tumors, particularly low-grade gliomas)
• Chondrosarcomas (bone cancer)

The discovery of these mutations has led to the development of targeted therapies, such as enasidenib, which specifically inhibits the mutant IDH2 enzyme, offering a more personalized approach to cancer treatment for patients harboring these genetic alterations.